Brain Sci. 2013, 3(1), 215-238; doi:10.3390/brainsci3010215
Article

The Protective Effect of Glibenclamide in a Model of Hemorrhagic Encephalopathy of Prematurity

1 Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201, USA 2 Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA 3 Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
* Author to whom correspondence should be addressed.
Received: 6 January 2013; in revised form: 21 February 2013 / Accepted: 22 February 2013 / Published: 7 March 2013
(This article belongs to the Special Issue Neuroprotection against Ischemic Brain Injury)
PDF Full-text Download PDF Full-Text [2535 KB, uploaded 7 March 2013 09:00 CET]
Abstract: We studied a model of hemorrhagic encephalopathy of prematurity (EP) that closely recapitulates findings in humans with hemorrhagic EP. This model involves tandem insults of 20 min intrauterine ischemia (IUI) plus an episode of elevated venous pressure induced by intraperitoneal glycerol on post-natal day (P) 0. We examined Sur1 expression, which is upregulated after focal ischemia but has not been studied after brief global ischemia including IUI. We found that 20 min IUI resulted in robust upregulation of Sur1 in periventricular microvessels and tissues. We studied tandem insult pups from untreated or vehicle-treated dams (TI-CTR), and tandem insult pups from dams administered a low-dose, non-hypoglycemogenic infusion of the Sur1 blocker, glibenclamide, for 1 week after IUI (TI-GLIB). Compared to pups from the TI-CTR group, pups from the TI-GLIB group had significantly fewer and less severe hemorrhages on P1, performed significantly better on the beam walk and accelerating Rotarod on P35 and in tests of thigmotaxis and rapid learning on P35–49, and had significantly greater body and brain weights at P52. We conclude that low-dose glibenclamide administered to the mother at the end of pregnancy protects pups subjected to IUI from post-natal events of elevated venous pressure and its consequences.
Keywords: encephalopathy of prematurity; germinal matrix hemorrhage; intraventricular hemorrhage; choroid plexus hemorrhage; sulfonylurea receptor 1; glibenclamide

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Tosun, C.; Koltz, M.T.; Kurland, D.B.; Ijaz, H.; Gurakar, M.; Schwartzbauer, G.; Coksaygan, T.; Ivanova, S.; Gerzanich, V.; Simard, J.M. The Protective Effect of Glibenclamide in a Model of Hemorrhagic Encephalopathy of Prematurity. Brain Sci. 2013, 3, 215-238.

AMA Style

Tosun C, Koltz MT, Kurland DB, Ijaz H, Gurakar M, Schwartzbauer G, Coksaygan T, Ivanova S, Gerzanich V, Simard JM. The Protective Effect of Glibenclamide in a Model of Hemorrhagic Encephalopathy of Prematurity. Brain Sciences. 2013; 3(1):215-238.

Chicago/Turabian Style

Tosun, Cigdem; Koltz, Michael T.; Kurland, David B.; Ijaz, Hina; Gurakar, Melda; Schwartzbauer, Gary; Coksaygan, Turhan; Ivanova, Svetlana; Gerzanich, Volodymyr; Simard, J. M. 2013. "The Protective Effect of Glibenclamide in a Model of Hemorrhagic Encephalopathy of Prematurity." Brain Sci. 3, no. 1: 215-238.

Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert